Site Editor

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

News

Predicting Overall Survival in Metastatic NSCLC: Daily Step Count vs ECOG Performance Status

News

AACR 2026: Zoldonrasib Shows Promising Responses in KRAS G12D–Mutated Lung Cancer

Medical Literature

Bevacizumab Study Shows Reduced ILD Risk in Advanced NSCLC

News

Zidesamtinib Approved for Second-Line Treatment of ROS1-Positive NSCLC

News

ASCO 2026: Adjuvant Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

Medical Literature

Blood Transfusions During Nivolumab Linked to Worse Survival in Metastatic NSCLC

David R. Spigel, MD, FASCO, on Guiding Adjuvant Chemotherapy Using a Molecular Assay

Jamie E. Chaft, MD, FASCO, on Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC

View More

Advertisement

JNCCN Spotlights

Repotrectinib for ROS1-Positive NSCLC

(NEW Update) Nivolumab in NSCLC

(NEW Update) Pembrolizumab in NSCLC

Dabrafenib + Trametinib (Tafinlar + Mekinist)

(UPDATE) Nivolumab (Opdivo) in NSCLC

Sotorasib

View More

More

News

Guideline-Concordant Lymph Node Sampling Does Not Increase Complications After NSCLC Resection

Zidesamtinib Approved for Second-Line Treatment of ROS1-Positive NSCLC

ASCO 2026: HARMONi-6 Meets Overall Survival Endpoint in Advanced Squamous NSCLC

ASCO 2026: Adjuvant Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

AACR 2026: Zoldonrasib Shows Promising Responses in KRAS G12D–Mutated Lung Cancer

Predicting Overall Survival in Metastatic NSCLC: Daily Step Count vs ECOG Performance Status

Zongertinib Approved for Unresectable or Metastatic Nonsquamous NSCLC

Cost Advantage of Sotorasib in KRAS G12C–Mutated NSCLC

View More

Advertisement

Published

Medical Literature

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

Heat Shock Protein 90 Inhibitor in Lung Cancer: GALAXY Clinical Trials

Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness

View More

Ongoing

CE Activities

Improving Lung Cancer Care Through Understanding the Patient Experience

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View More

Available

Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2026 National Comprehensive Cancer Network, All Rights Reserved